Contribuição ao estudo da Tripanosomiase Americana

1) Em trabalho sistematizado, foi estudada pela primeira vez a epidemiologia da doença de Chagas, em um trecho da região do estuário do Amazonas, cujas condições ecológicas diferem das encontradas em outras zonas onde teem sido feitas pesquisas semelhantes. 2) No local escolhido para estudo – Aura – uma localidade distante cerca de 10 km. de Belém, (Pará), não foi encontrada nenhuma infecção humana pelo S. cruzi, quer pelo exame de sangue, quer pelo xenodiagnóstico, ambos feitos em todos os habitantes (117 indivíduos). Não foi encontrada também sintomatologia atribuível à doença. 3) Em 6 xenodiagnósticos feitos em animais domésticos (5 cães e 1 gato), foi encontrado um cão infectado. Este animal pertencia á casa onde foi verificada maior infestação por Triatomídeos, com índice de infecção elevado. Pelas razões expostas no texto, porem, foi sugerida a hipótese do mesmo se ter infectado pela ingestão de vísceras de animais silvestres contaminados. 4) De 115 animais silvestres, cujo sangue foi examinado em gota espessa, 9 mostraram-se parasitados por Schizotrypanum (7,8%). Em 47 verificações pelo xenodiagnóstico, 15 animais silvestres (11 mucuras, 3 tamanduás e 1 tatú) se apresentaram positivos (32,6%) . O tamanduá (T. tetradactylus) foi pela primeira vez assinalado como depositário natural do Schizotrypanum. 5) Como resultado de buscas feitas durante 11 meses, sendo cada domicílio inspecionado pelo menos de 15 em 15 dias, foram encontrados Triatomídeos em 7 das 36 casas existentes no povoado. Todos os 39 exemplares capturados eram adultos; a procura exaustiva não revelou a existência de formas jovens no interior das habitações. Na ordem de freqüência, as espécies encontradas foram as seguintes: P. geniculatus (29 exemplares, dos quais 7 infectados); R. pictipes ( 9 exemplares, dos quais 2 infectados); E. mucronatus ( 1 exemplar, não infectado) . A grande maioria dos insetos foi capturada na segunda metade do ano (época do estío). 6) Em plena mata, n’uma toca de tamanduá (T. tetradactylus) foram encontradas larvas, ninfas e adultos de P. geniculatus. A casa situada mais próximo desse foco, foi a que apresentou maior infestação (22 exemplares) e exclusiva para essa espécie. Em uma toca de macaco da noite (P. flavus), foi encontrada uma larva de Triatomídeo. Este foco também ficava próximo à casa acima referida. Em toca de P. flavus foi também achado um exemplar adulto de Panstrongylus refotuberculatus. 7) Amostras de S. cruzi isoladas de animais silvestres, mostraram fraco poder infectante. A amostra isolada do cão, embora infectando facilmente os animais de laboratório, pelos estudos biométricos feito por DIAS e FREITAS, afasta-se das amostras humanas típicas. 8) São discutidos os resultados acima referidos e, pelos hábitos dos transmissores, pela predominância de depositários silvestres do parasito, conclue-se pela natureza silvestre da Tripanosomiase Americana no local estudado. Se bem que não tenham sido verificadas infecções humanas, dado o encontro de um cão parasitado – infecção esta que se pode ter verificado pelo meio normal da transmissão da moléstia – admite-se a possibilidade do aparecimento de casos humanos nessa região. Ressalta-se a confirmação que tais resultados parecem trazer á hipótese de CARLOS CHAGAS, que pensava ser esta doença primitivamente silvestre, com posterior adaptação aos animais domésticos e ao homem.

7ª Contribuição ao estudo dos Flebotomus (Diptera: Psychodidae): descrição dos machos de 24 novas espécies

The A. and his co-workers captured in trips in the hinterland of Brazil more tham 17.000 flebotomi from which 35 are new ones, 11 discribed by, him in previous papers. The A. found these insects in groups of species living in different habitats, some ones of them not yet known: ondoors, or outdoors attracted by light or animal baits, without Shannon’s trap, in great or small caves, in the jungle in tree’s holes, holes in stones, holes in the soil habited by animals like armadillos, pacas (Aguti paca), wild rats, cururú toad (Bufo sp.). He observed the life history of 13 species: Flebotomus longipalpis Lutz& Neiva, 1912, Flebotomus intermedius Lutz & Neiva, 1912, Flebotomus avellari Costa Lima, 1932, Flebotomus aragãoi costa Lima, 1932, Flebotomus lutzianus Costa Lima, 1932, Flebotomus limai fonseca, 1935, Flebotomus rickardi Costa Lima, 1936, Flebotomus dasipodogeton Castro, 1939, Flebotomus oswaldoi n. sp., Flebotomus villelai n. sp., Flebotomus triacanthus n. sp., Flebotomus longispinus n. sp. And flebotomus travassosi n. sp. He describes the male of 24 n. sp., explaining the differential diagnose of group or nearly allied species. He inclued F. rooti n. sp. And F. hirsutus n. sp. In the sub-genus Shannonomyia. The first one, very allied to F. davisi Root is different from it, for presenting in the dorsal side of the abdomen bristles and not scales and to have the median claspers longer than his inner appendage and F. hirsutus quite different from the others which show 3 spines on distal segment of the upper clasper and for being the only one who presents the bristles of inner appendage of median clasper longer than it. Only the females of F. amazonensis Root and f. chagasi Costa Lima, are known and then it is possible that they belong to one of the species of this sub-genus from whom only the male have been described. F. choti Floch & Abonnenc, captured also at Pará, F. triacanthus n. sp. F. trispinosus n. sp. And F. equatorialis n. sp. Are very related and to this group the A. proposes the same of Pressatia as sub-genus in honor to whom demonstrated the medical importance of the flebotomi, considering F. triacanthus as the type specie of this sub-genus. In this sub-genus the V papal joint is very long, longer than III + IV, the antennae with geniculated spines without posterior outgrowth. At the genitalia the basal segment of the upper clasper presents two types of bristles ou the inner face, arranged in tuft; the distal segment with 3 spines and 2 thin bristles something difficult to see one of them situated near the apical spine and the other on the base of tubercle where the median spine is articulated; the median clasper is unarmed and compressed; the inferior clasper is also unarmed and longer than de basal segment of the upper clasper; the pompeta is longer than the basal segment of the upper clasper. Following it is presented a key for the determination of the males of the four species of this sub-genus. F. micropygus n. sp., F. minasensis n. sp. e F. dandrophylus n. sp., f. shannoni, F. monticolus, F. pestanai, F. lanei and F. cayenensis constitute a group with many similars characters. F. micropygus is the only American species who present α smaller than β and for that reason and others is allied to. F. minuts and others related species, but presents two terminal spines on the distal segment of the upper clasper. F. micropygus and f. minasensis are quite different because they have very small genitalia, smaller than their heads. F. dendrophylus presents on the median clasper a naked area near the apex and for this and others characters is different from the others of the group. F. flaviscutellatus n. sp., F. oliverioi, F. intermedius and whithmani, are very allied but the first one can be very easily distinguished because it’s scutellum is light. Flebotomus barrettoi n. sp., F. coutinhoi n. sp., F. aragãoi, F. brasiliensis, F. lutzianus, F. texanus, F. pascalei, F. atroclavatus and F. tejeraae are very allied forming a natural group. The two last ones are not well known but the A. A. who have studied them described very long clipeus so long as the head and for that reason can be distinguished from all the others included the two new ones. F. coutinhoi is the only one who presents the apecis of the penis filaments twisted. F. barrettoi n. sp., can be distinguished from aragãoi, texamus and coutinhoi by the length of the penis filaments and from atrocavatus, tejeraae, lutzianus and brasiliensis by the arrangement of the spines of distal segment of the upper clasper. Flebotomus ubiquitalis n. sp., F. auraensis n. sp., F. affinis and F. microps e F. antunesi have many common characters. F. microps n. sp., can be distinguished from any one by the size of the eyes and the presence od well developed genae. This species and other new species are different from F. antunesi by the arrangement of the spines of the distal segment of the upper clasper of the latter. F. ubiquitalis n. sp. can be distinguished from others by the figure of the median clasper. F. auraensis n. sp. Can be distinguished from F. affinis n. sp. By the tuft hairs on the inner face of the basal segment and by arrangement of the spines of the sital segment of the upper clasper. Flebotomus brachipygus n. sp. Seemed to be F. rostrans, specie not well known, by the characters of the genitalia but can not be identified to her by the clypeus size and the palpi’s characters. Flebotomus costalimai, n. sp., f. tupynambai n. sp., and f. castroi Barreto & Coutinho, 1941, are very allied species and the A. proposes to included them the new sub-genus Castromyia, in honor to Dr. G. M. de Oliveira Castro, appointing like typespecies F. castroi with the V joint longer than III + IV; antennae with geniculated spines without posterior prolongation. Genitalia: the basal segment of the upper clasper with a tuft of hairs and the distal segment with 4 spines, one of them at the apex and near it a thin and straight bristle difficult to see; the median clasper with one spinous hair isolated...

Pesquisas sobre a imunidade da Framboesia tropica no homem: observações feitas em 33 superinoculações e 7 reinoculações

Como resultado das 40 experiências relatadas neste trabalho, as seguintes conclusões podem ser tiradas: 1) Dos 2 até aos 8 meses de molestia há na bouba uma grande resistência á superinoculação (13 experiências negativas em 15). Nas 2 experiências positivas, foram obtidas lesões atípicas (pianides): a) Tal resistência parece independer da presença de lesões boubaticas cutaneas e se fez sentir mesmo em casos com a lesão inicial exclusiva. b) Dentro desse período de molestia, tal resistência pode desaparecer com o tratamento: 2 doentes tratados aos 6 meses e reinoculados adquiriram bouba em tempo normal. Porém, um caso tratado aos 7 meses e reinoculado, desenvolveu uma pianide. Êste fato parece mostrar que essa resistência depende principalmente da presença da infecção ativa ou latente, raramente traduzindo uma imunidade no verdadeiro sentido do têrmo. c) No caso de emprego de homo-virus, essa resistência prolongou-se até um ano d molestia, havendo apenas um caso duvidoso em 10 inoculações. 2) Do 10º mês ao 4º ano de molestia, em 8 superinoculações observou-se uma resistência parcial que se traduziu de 2 modos, quanto à natureza da lesão atípica que se obteve no ponto inoculado; "lesão frustra papulo-eritematosa" (7 meses); e lesão semelhante ás "pianides" da infecção natural (1 vez), a qual permaneceu localizada sem manifestações metastaticas, até 4 meses de observação. a) Também este estado de resistência parcial, parece independer da presença de lesões boubaticas aparentes. b) Com o tratamento esse estado parece não se modificar: um doente tratado nesse período da molestia, reagiu à inoculação de modo semelhante, embora sem nenhuma manifestação clínica e com a R. Wa. negativa. Inegavelmente, essas "lesões frustras" e também as "pianides" obtidas, representam respostas de organismos que obtiveram vantagens na luta com a doença, possuindo um certo grau de imunidade, que é muitíssimo maior no caso das primeiras. 3) Depois do 5º ano de molestia, a resposta á superinoculação traduziu um estado de maior sensibilidade do organismo infectado. Observou-se no ponto inoculado uma reação precoce papulo-eritemato-ulcerosa, francamente necrotica e destrutiva, ao mesmo tempo que se verificou exacerbação das lesões dos pacientes, com grande infartamento gangliomar satélite. Até 18 meses depois, em um caso, a lesão obtida permaneceu localizada sem manifestações generalizadas. a) O tratamento não modificou tal estado. Doentes tratados ( e parcial ou totalmente curados), reagiram da mesma maneira à reinoculação dentro desse período da molestia. Apenas em um caso de mais de 5 anos (nº 40) não se obteve a lesão ulcero-necrotica. Era o único dos 13 experimentados que não tinha nem tivera lesões ulcero-gomoides destrutivas. por outro lado, 2 pacientes apresentando lesões gomo-ulcerativas, mas tendo menos de 3 anos de molestia, não deram a lesão ulcerativo-necrotica em resposta à superinoculação. (Experiências ns. 38 e 39). Interessante é que esta lesão ulcerativo-necrotica contém treponemas embora raros, e em evolução pode tomar o carater das lesões destrutivas gomo-ulcerativas peculiares ao chamado "período terciario" da doença, com as quais também se assemelha histopatológicamente. Sob o ponto de vista imunológico, esta lesão representa um estado de maior sensibilidade do organismo para o agente infeccioso. 4) Como o tratamento precoce perturba o desenvolvimento da imunidade, sob o ponto de vista epidemiológico, seria aconselhável aguardar o período terminal do chamado secundarismo, isto é da fase de generalização boubatica, para tratar os pacientes em Postos, hospitais ou ambulatórios pois, tais doentes poderiam se reinfestar uma vez retornados ao fóco. Claro que em campanhas terapeuticas profilaticas, as lesões "abertas" primo-secundarias, devem ser rapidamente eliminadas uma vez que são as mais contagiantes, por mais ricas em germes. 5) Existe na framboesia trópica uma verdadeira imunidade além de uma simples resistência á superinoculação devido a presença da infecção ativa ou latente. Com efeito, pacientes tratados em determinado período da molestia e curados clinica e sorologicamente, mostraram resistência parcial á reinoculação, reagindo de modo semelhante a outros do mesmo período de molestia e não tratados. 6) A imunidade na framboesia tropica se manifesta seja como uma resistência á superinoculação ou reinoculação seja como uma modificação da lesão boubatica inicial, seja, finalmente, como uma resistência á generalização da doença. 7) Os resultados das esperiências sugerem que as diferentes manifestações cutaneas da molestia são condicionadas até certo ponto pelo estado imunitario do organismo infectado. 8) Os diferentes gráus de imunidade, encontrados na framboesia trópica, estão até certo ponto relacionados com o tempo de doença. Porém, são atingidos mais ou menos ràpidamente, segundo o organismo infectado e, talvez segundo a virulência do treponema, do mesmo modo como os chamados "secundarismo" e 'terciarismo" da doença.

Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study.

BACKGROUND: Patterns of morbidity and mortality among human immunodeficiency virus (HIV)-infected individuals taking antiretroviral therapy are changing as a result of immune reconstitution and improved survival. We studied the influence of aging on the epidemiology of non-AIDS diseases in the Swiss HIV Cohort Study. METHODS: The Swiss HIV Cohort Study is a prospective observational cohort established in 1988 with continuous enrollment. We determined the incidence of clinical events (per 1000 person-years) from January 2008 (when a new questionnaire on non-AIDS-related morbidity was introduced) through December 2010. Differences across age groups were analyzed using Cox regression, adjusted for CD4 cell count, viral load, sex, injection drug use, smoking, and years of HIV infection. RESULTS: Overall, 8444 (96%) of 8848 participants contributed data from 40,720 semiannual visits; 2233 individuals (26.4%) were aged 50-64 years, and 450 (5.3%) were aged ≥65 years. The median duration of HIV infection was 15.4 years (95% confidence interval [CI], 9.59-22.0 years); 23.2% had prior clinical AIDS. We observed 994 incident non-AIDS events in the reference period: 201 cases of bacterial pneumonia, 55 myocardial infarctions, 39 strokes, 70 cases of diabetes mellitus, 123 trauma-associated fractures, 37 fractures without adequate trauma, and 115 non-AIDS malignancies. Multivariable hazard ratios for stroke (17.7; CI, 7.06-44.5), myocardial infarction (5.89; 95% CI, 2.17-16.0), diabetes mellitus (3.75; 95% CI, 1.80-7.85), bone fractures without adequate trauma (10.5; 95% CI, 3.58-30.5), osteoporosis (9.13; 95% CI, 4.10-20.3), and non-AIDS-defining malignancies (6.88; 95% CI, 3.89-12.2) were elevated for persons aged ≥65 years. CONCLUSIONS: Comorbidity and multimorbidity because of non-AIDS diseases, particularly diabetes mellitus, cardiovascular disease, non-AIDS-defining malignancies, and osteoporosis, become more important in care of HIV-infected persons and increase with older age.

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).

BACKGROUND: The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment. PATIENTS AND METHODS: This is a phase II, open, multicenter, noncomparative study. Two patient groups were prospectively considered: group A (n=70) with AI-responsive disease and group B (n=20) with AI-resistant disease. Fulvestrant 250 mg was administered as intramuscular injection every 28 (+/-3) days. RESULTS: All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases and 45% liver metastases. Fulvestrant administration was well tolerated and yielded a clinical benefit (CB; defined as objective response or stable disease [SD] for >or=24 weeks) in 28% (90% confidence interval [CI] 19% to 39%) of patients in group A and 37% (90% CI 19% to 58%) of patients in group B. Median time to progression (TTP) was 3.6 (95% CI 3.0 to 4.8) months in group A and 3.4 (95% CI 2.5 to 6.7) months in group B. CONCLUSIONS: Overall, 30% of patients who had progressed following prior AI treatment gained CB with fulvestrant, thereby delaying indication to start chemotherapy. Prior response to an AI did not appear to be predictive for benefit with fulvestrant.

Pregnancy Outcome Following Maternal Exposure To Statins: A Multicenter Prospective Study

Introduction: Statin use for the treatment of hypercholesterolemia in women of childbearing age is increasingly common. However, published data on pregnancy outcome after exposure to statins are scarce and conflicting. This contribution addresses the safety of exposure to statins during pregnancy.Method: In a multi-center (n = 11) observational, prospective study we compared the outcomes of 249 women exposed during the 1st trimester of pregnancy to simvastatin (n = 124), atorvastatin (n = 67), pravastatin (n = 32), rosuvastatin (n = 18), fluvastatin (n = 7) or cerivastatin (n = 1) with a control group exposed to agents known to be non-teratogenic (n = 249). The data were collected by members of the European Network of Teratology Information Services (ENTIS) during individual risk counseling between 1990 and 2009. Standardized procedures for data collection were used in each center.Results: The difference in the rate of major birth defects between the statin-exposed group and the control group was not statistically significant (4.0% vs. 2.7% OR 1.5; 95% CI 0.5-4.5, P = 0.44). The crude rate of spontaneous abortions (12.8% vs. 7.1%, OR 1.9, 95% CI 1.0-3.6, P = 0.04) was higher in the exposed group. However, after adjustment to maternal age and gestational age at initial contact, the difference became statistically insignificant. The rate of elective pregnancy-termination (8.8% vs. 4.4%, P = 0.05) was higher and the rate of deliveries resulting in live births was significantly lower in the statin exposed group (77.9% vs. 88.4%, P = 0.002). Prematurity was more frequent in exposed pregnancies (16.1% vs. 8.5%; OR 2.1, 95% CI 1.1-3.8, P = 0.02). Nonetheless, gestational age at birth (median 39 weeks, IQR 37-40 vs. 39 weeks, IQR 38-40, P = 0.27) and birth weight (median 3280 g, IQR 2835-3590 vs. 3250 g, IQR 2880-3600, P = 0.95) did not differ between exposed and non-exposed pregnancies.Conclusion: This study did not detect a clear teratogenic effect of statins. Its statistical power however is not sufficient to reverse the recommendation of treatment discontinuation during pregnancy. At most, the results are reassuring in case of inadvertent exposure.

Skeletal Muscle Mitochondrial and Lipid Droplet Volume Density: Validity of Electron Microscopy Point-counting Measurements

Mitochondrial (M) and lipid droplet (L) volume density (vd) are often used in exercise research. Vd is the volume of muscle occupied by M and L. The means of calculating these percents are accomplished by applying a grid to a 2D image taken with transmission electron microscopy; however, it is not known which grid best predicts these values. PURPOSE: To determine the grid with the least variability of Mvd and Lvd in human skeletal muscle. METHODS: Muscle biopsies were taken from vastus lateralis of 10 healthy adults, trained (N=6) and untrained (N=4). Samples of 5-10mg were fixed in 2.5% glutaraldehyde and embedded in EPON. Longitudinal sections of 60 nm were cut and 20 images were taken at random at 33,000x magnification. Vd was calculated as the number of times M or L touched two intersecting grid lines (called a point) divided by the total number of points using 3 different sizes of grids with squares of 1000x1000nm sides (corresponding to 1µm2), 500x500nm (0.25µm2) and 250x250nm (0.0625µm2). Statistics included coefficient of variation (CV), 1 way-BS ANOVA and spearman correlations. RESULTS: Mean age was 67 ± 4 yo, mean VO2peak 2.29 ± 0.70 L/min and mean BMI 25.1 ± 3.7 kg/m2. Mean Mvd was 6.39% ± 0.71 for the 1000nm squares, 6.01% ± 0.70 for the 500nm and 6.37% ± 0.80 for the 250nm. Lvd was 1.28% ± 0.03 for the 1000nm, 1.41% ± 0.02 for the 500nm and 1.38% ± 0.02 for the 250nm. The mean CV of the three grids was 6.65% ±1.15 for Mvd with no significant differences between grids (P>0.05). Mean CV for Lvd was 13.83% ± 3.51, with a significant difference between the 1000nm squares and the two other grids (P<0.05). The 500nm squares grid showed the least variability between subjects. Mvd showed a positive correlation with VO2peak (r = 0.89, p < 0.05) but not with weight, height, or age. No correlations were found with Lvd. CONCLUSION: Different size grids have different variability in assessing skeletal muscle Mvd and Lvd. The grid size of 500x500nm (240 points) was more reliable than 1000x1000nm (56 points). 250x250nm (1023 points) did not show better reliability compared with the 500x500nm, but was more time consuming. Thus, choosing a grid with square size of 500x500nm seems the best option. This is particularly relevant as most grids used in the literature are either 100 points or 400 points without clear information on their square size.

The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients.

BACKGROUND: Among patients with steroid-refractory ulcerative colitis (UC) in whom a first rescue therapy has failed, a second line salvage treatment can be considered to avoid colectomy. AIM: To evaluate the efficacy and safety of second or third line rescue therapy over a one-year period. METHODS: Response to single or sequential rescue treatments with infliximab (5mg/kg intravenously (iv) at week 0, 2, 6 and then every 8weeks), ciclosporin (iv 2mg/kg/daily and then oral 5mg/kg/daily) or tacrolimus (0.05mg/kg divided in 2 doses) in steroid-refractory moderate to severe UC patients from 7 Swiss and 1 Serbian tertiary IBD centers was retrospectively studied. The primary endpoint was the one year colectomy rate. RESULTS: 60% of patients responded to the first rescue therapy, 10% went to colectomy and 30% non-responders were switched to a 2(nd) line rescue treatment. 66% of patients responded to the 2(nd) line treatment whereas 34% failed, of which 15% went to colectomy and 19% received a 3(rd) line rescue treatment. Among those, 50% patients went to colectomy. Overall colectomy rate of the whole cohort was 18%. Steroid-free remission rate was 39%. The adverse event rates were 33%, 37.5% and 30% for the first, second and third line treatment respectively. CONCLUSION: Our data show that medical intervention even with 2(nd) and 3(rd) rescue treatments decreased colectomy frequency within one year of follow up. A longer follow-up will be necessary to investigate whether sequential therapy will only postpone colectomy and what percentage of patients will remain in long-term remission.

Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study.

We sought to provide a contemporary picture of the presentation, etiology, and outcome of infective endocarditis (IE) in a large patient cohort from multiple locations worldwide. Prospective cohort study of 2781 adults with definite IE who were admitted to 58 hospitals in 25 countries from June 1, 2000, through September 1, 2005. The median age of the cohort was 57.9 (interquartile range, 43.2-71.8) years, and 72.1% had native valve IE. Most patients (77.0%) presented early in the disease (<30 days) with few of the classic clinical hallmarks of IE. Recent health care exposure was found in one-quarter of patients. Staphylococcus aureus was the most common pathogen (31.2%). The mitral (41.1%) and aortic (37.6%) valves were infected most commonly. The following complications were common: stroke (16.9%), embolization other than stroke (22.6%), heart failure (32.3%), and intracardiac abscess (14.4%). Surgical therapy was common (48.2%), and in-hospital mortality remained high (17.7%). Prosthetic valve involvement (odds ratio, 1.47; 95% confidence interval, 1.13-1.90), increasing age (1.30; 1.17-1.46 per 10-year interval), pulmonary edema (1.79; 1.39-2.30), S aureus infection (1.54; 1.14-2.08), coagulase-negative staphylococcal infection (1.50; 1.07-2.10), mitral valve vegetation (1.34; 1.06-1.68), and paravalvular complications (2.25; 1.64-3.09) were associated with an increased risk of in-hospital death, whereas viridans streptococcal infection (0.52; 0.33-0.81) and surgery (0.61; 0.44-0.83) were associated with a decreased risk. In the early 21st century, IE is more often an acute disease, characterized by a high rate of S aureus infection. Mortality remains relatively high.

Reduction of small infrarenal abdominal aortic aneurysm expansion rate by statins.

BACKGROUND: To evaluate the effect of statins on the annual expansion rate (ER) of small infrarenal abdominal aortic aneurysms (AAA). PATIENTS AND METHODS: All patients under regular surveillance for small AAA between January 2000 and September 2007, in the Department of Angiology, Lausanne University Hospital, were included. Inclusion criteria were baseline abdominal aortic diameter between 25 and 55 mm, at least two measurements of AAA diameter and a minimum follow up of 6 months. Patients with Marfan disease, infectious or inflammatory AAA, and patients with prior AAA repair were excluded. The influence of statin use and other factors on ER were examined by bivariate and multivariate analysis. RESULTS: Among 589 patients who underwent an abdominal aorta evaluation, 94 patients (89 % men, mean age 69.1 years) were finally included in the analysis. Baseline AAA size was 39.9 ± 7.7 mm (mean±SE) and 48.7 ± 8.4 mm at end of follow-up. Patients had a regular aneurysm size assessment during 38.5 ± 27.7 months. Mean ER was 3.59 mm/y (± 2.81). The 50 patients who were treated with statin during the study period had a lower ER compared to the 44 controls (2.91 vs 4.37 mm/year, p = 0.01). CONCLUSIONS: This study confirms the considerable individual variations in the AAA expansion rate, and emphasizes the need for regular aortic diameter assessments. In this study, patients treated with statin demonstrate a significant decrease in the ER compared to controls. This finding need to be evaluated in prospective interventional studies powered to demonstrate the potential benefit of statin treatment.

Plasma Level of Mmp-9 as Predictive Factor for Response and Progression Free Survival in Patients Treated with Bevacizumab (Bev) and Pegylated Liposomal Doxorubicin (Pld): Sakk 24/06

Background: There is currently no identified marker predicting benefit from Bev in patients with breast cancer (pts). We monitored prospectively 6 angiogenesis-related factors in the blood of advanced stage pts treated with a combination of Bev and PLD in a phase II trial of the Swiss Group for Clinical Cancer Research, SAKK.Methods: Pts received PLD (20 mg/m2) and Bev (10 mg/kg) every 2 weeks for a maximum of 12 administrations, followed by Bev monotherapy until progression or severe toxicity. Blood samples were collected at baseline, during treatment and at treatment discontinuation. Enzyme-linked immunosorbent assays (Quantikine, R&DSystems and Reliatech) were used to measure vascular endothelial growth factor (VEGF), placental growth factor (PlGF), matrix metalloproteinase 9 (MMP-9) and soluble VEGF receptors -1, -2 and -3. The natural log-transformed (ln) data for each factor was analyzed by analysis of variance (ANOVA) model to investigate differences between the mean values of the subgroups of interest (where a = 0.05), based on the best tumor response by RECIST.Results: 132 samples were collected in 41 pts. The mean of baseline ln MMP-9 levels was significantly lower in pts with tumor progression than those with tumor response (p=0.0202, log fold change=0.8786) or disease control (p=0.0035, log fold change=0.8427). Higher MMP-9 level was a significant predictor of superior progression free survival (PFS): p=0.0417, hazard ratio=0.574, 95% CI=0.336-0.979. In a multivariate cox proportional hazards model, containing performance status, disease free interval, number of tumor sites, visceral involvement and prior adjuvant chemotherapy, using stepwise regression baseline MMP-9 was still a statistically 117P Table 1. SOLTI-0701* AC01B07* NU07B1* SOR+CAP N=20 PL+CAP N=33 SOR+ GEM/CAP N=23 PL+ GEM/CAP N=27 SOR+PAC N=48 PL+PAC N=46 Baseline characteristics Age, median (range), y 49 (32-72) 53 (30-78 54 (32-69) 57 (31-82) 50 (27-80) 52 (23-74) AJCC stage, n (%) IIIB/IIIC 3 (15) 6 (18) 0 (0) 3 (11) 8 (17) 9 (20) IV 17 (85) 27 (82) 23 (100) 24 (89) 40 (83) 37 (80) Metastatic site, n (%) Non-visceral 3 (15) 6 (18) 7 (30) 6 (22) 9 (19) 17 (37) Visceral 17 (85) 27 (82) 16 (70) 21 (78) 39 (81) 29 (63) Prior metastatic chemo, n (%) 8 (40) 15 (45) 21 (91) 25 (93) - - Efficacy PFS, median, mo 4.3 2.5 3.1 2.6 5.6 5.5 HR (95% CI)_ 0.60 (0.31, 1.14) 0.57 (0.30, 1.09) 0.86 (0.50, 1.45) 1-sided P value_ 0.055 0.044 0.281 Overall survival, median, mo 17.5 16.1 Pending 14.7 18.2 HR (95% CI)_ 0.98 (0.50, 1.89) 1.11 (0.64, 1.94) 1-sided P value_ 0.476 0.352 Safety N=20 N=33 N=22 N=27 N=46 N=46 Tx-emergent Grade 3/4, n (%) 15 (75) 16 (48) 20 (91) 17 (63) 36 (78) 16 (35) Grade 3§ hand-foot skin reaction/ syndrome 8 (40) 5 (15) 8 (36) 0 (0) 14 (30) 2 (4) *Efficacy results based on intent-to-treat population and safety results based on safety population (pts who received study drug[s]); _Cox regression within each subgroup; _log-rank test within each subgroup; §maximum toxicity grade for hand-foot skin reaction/syndrome; AJCC, American Joint Committee on Cancer mittedabstractsª The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com Downloaded from annonc.oxfordjournals.org at Bibliotheque Cantonale et Universitaire on June 6, 2011 significant factor (p=0.0266). The results of the other measured factors were presented elsewhere.Conclusions: Higher levels of MMP-9 could predict tumor response and superior PFSin pts treated with a combination of Bev and PLD. These exploratory results justify further investigations of MMP-9 in pts treated with Bev combinations in order to assess its role as a prognostic and predictive factor.Disclosure: K. Zaman: Participation in advisory board of Roche; partial sponsoring ofthe study by Roche (the main sponsor was the Swiss Federation against Cancer (Oncosuisse)). B. Thu¨rlimann: stock of Roche; Research grants from Roche. R. vonMoos: Participant of Advisory Board and Speaker honoraria

Sudden cardiac death in the young (5-39 years) in the canton of Vaud, Switzerland.

BACKGROUND: Sudden cardiac death (SCD) among the young is a rare and devastating event, but its exact incidence in many countries remains unknown. An autopsy is recommended in every case because some of the cardiac pathologies may have a genetic origin, which can have an impact on the living family members. The aims of this retrospective study completed in the canton of Vaud, Switzerland were to determine both the incidence of SCD and the autopsy rate for individuals from 5 to 39 years of age. METHODS: The study was conducted from 2000 to 2007 on the basis of official statistics and analysis of the International Classification of Diseases codes for potential SCDs and other deaths that might have been due to cardiac disease. RESULTS: During the 8 year study period there was an average of 292'546 persons aged 5-39 and there were a total of 1122 deaths, certified as potential SCDs in 3.6% of cases. The calculated incidence is 1.71/100'000 person-years (2.73 for men and 0.69 for women). If all possible cases of SCD (unexplained deaths, drowning, traffic accidents, etc.) are included, the incidence increases to 13.67/100'000 person-years. However, the quality of the officially available data was insufficient to provide an accurate incidence of SCD as well as autopsy rates. The presumed autopsy rate of sudden deaths classified as diseases of the circulatory system is 47.5%. For deaths of unknown cause (11.1% of the deaths), the autopsy was conducted in 13.7% of the cases according to codified data. CONCLUSIONS: The incidence of presumed SCD in the canton of Vaud, Switzerland, is comparable to the data published in the literature for other geographic regions but may be underestimated as it does not take into account other potential SCDs, as unexplained deaths. Increasing the autopsy rate of SCD in the young, better management of information obtained from autopsies as well developing of structured registry could improve the reliability of the statistical data, optimize the diagnostic procedures, and the preventive measures for the family members.

Analysis of Mycobacterium avium Complex Serovars Isolated from AIDS Patients from Southeast Brazil

The purpose of this study was to assess the distribution of Mycobacterium avium serovars isolated from AIDS patients in São Paulo and Rio de Janeiro. Ninety single site or multiple site isolates from 75 patients were examined. The most frequent serovars found were 8 (39.2%), 4 (21.4%) and 1 (10.7%). The frequency of mixed infections with serovar 8 or 4 was 37.8%. Among the 90 strains examined, M. intracellulare serovars (7 strains) and M. scrofulaceum (4 strains) were found in 11 isolates (12%) indicating that M. avium (88%) was the major opportunistic species in the M. avium complex isolates in Brazilian AIDS patients

Prolonged antiretroviral therapy initiated at seroconversion is associated with a polyfunctional HIV-1-specific T-cell profile comparable to that of long-term non-progressors (LTNPs)

Background: Early initiation of antiretroviral therapy (ART) may dramatically curtail cumulative immunological damage allowing maximal levels of immune preservation/reconstitution and induce an immunovirological status similar to that of HIV-1 LTNPs with low viral reservoirs and polyfunctional HIV-1 specific T cell responses.Methods: We performed a cross-sectional study of an HIV-1 seroconverter cohort on long-term ART (LTTS) and compared it to one of LTNPs. Inclusion criteria for 20 LTTS were: (a) ?4 years ART; (b) long-term aviremia and (c) absence of treatment failure and for 15 LTNPs: (a) ?7 years of documented HIV-1 infection; (b) <1000 HIV-1 RNA copies/mL and ?500 CD4+ T-cells/mm3 in >90% of measurements; (d) absence of AIDS-defining conditions; (e) ART-naı¨ve except for temporary ART for prevention of MTCT. In both cohorts, we analysed residual viral replication and reservoirs in peripheral blood, as measured by cellassociated HIV-1 RNA and DNA in PBMCs, respectively and used polychromatic flow cytometry to analyse HIV-1-specific CD4+ and CD8+ T-cell functional profile in terms of cytokine production using IFN-c, IL-2, TNF-a production.Results: Cell-associated DNA [47.7 (4.8-583.2) in LTTS and 19.7 (0.5-295.5) in LTNPS, p=0.10], and RNA [3.9 (0-36) and 5.8 (0-10.3), respectively] were shown to be similarly low in both cohorts. We identified 103 CD8 T cell epitope-specific responses, all subjects responding to ?1 epitope. Mean responding number of responding epitopes per patient was 2 and 4 in LTTS and LTNPS, respectively. Mean% of cytokine-secreting CD8 T cells was 0.37% and 0.50% (p=0.06), of these 43% and 39% (p=0.12) were secreting simultaneously IFN-c, IL-2 and TNF-a. Respective values for CD4 T cells were 0.28% and 0.33% (p=0.28) of which 33% and 30% (0.32) were secreting these 3 cytokines simultaneously.Conclusions: Long-term aviremia after very early ART initiation is associated with low levels of reservoirs saturation ad residual replication. Although less broad CD8 T cell responses were found in LTTS, HIV-1 specific CD4 and CD8 T cell responses showed similar magnitude and functional profile in the 2 cohorts. Our results indicate that prolonged ART initiated at the time of HIV-1 seroconversion is associated with immuno-virological features which resemble those of LTNPs. (BHIVA Research Award Winner 2008: Anna Garcia-Diaz.)

The difference between the basal metabolic rate and the sleeping metabolic rate in Japanese.

Previous studies have demonstrated the difference between the basal metabolic rate (BMR) and the sleeping metabolic rate (SMR): however, the difference in the Japanese population has not yet been explored. This study examined the relationship between the BMR and SMR in ninety-four healthy Japanese subjects (37 males and 57 females, 39 +/- 12 y of age and 22.0 +/- 7.4% body fat) in a respiratory chamber. The SMR was significantly lower than the BMR (1416 +/- 245 vs. 1492 +/- 256 kcal/d): however, there was a highly significant correlation between the two (r = 0.867; p < 0.001). The ratio of SMR/BMR largely varied among individuals (0.95 +/-0.08, 8.4% of the coefficient of variation). The ratio was significantly lower in males than in females (0.93 +/- 0.10 vs. 0.97 +/- 0.06, p < 0.05). None of the anthropometric measures (age, weight, body mass index, body surface area or percent body fat) correlated with the ratio. These results showed that SMR was 95%, of BMR on average in a healthy Japanese group. However, when applied over a longer time period (24 h or more), the difference tends to become negligible for most analyses in a group. Although the difference between SMR and BMR will induce a 5% gap of physical activity level defined as the total energy expenditure divided by the BMR or SMR, this factor seems to have little practical importance in epidemiological research.